Add Formweb to your mobile device
Approved Formulary
Search results for:
lithium
lithium
Brand names: LithoBid, Lithotab
| Form | Strength |
|---|---|
| TABLET, EXTENDED RELEASE, ORAL | 300 mg |
| TABLET, ORAL | 300 mg |
Display Antimanic Agents Class:
282800
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | lithium (Eskalith, Lithobid) |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | lithium ⇄ ACEIs, ARBs, ARNIs |
| Risk Rationale | Increased risk of lithium toxicity. |
| Recommendation | Avoid; monitor lithium concentrations. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Interacting drug(s) or class(es) | lithium ⇄ Loop diuretics |
| Risk Rationale | Increased risk of lithium toxicity. |
| Recommendation | Avoid; monitor lithium concentrations. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
Last updated: Sep. 19, 2025
- Black Box Warnings Monitoring recommendations
- Look-Alike/Sound-Alike lithium confused with Ultram